Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Surgeon General Nominee Backs Obama's Positions On Reproductive Health, White House Says
The Washington Post reports that Regina Benjamin -- President Obama"s nominee for U.S. surgeon general -- shares Obama"s position on reproductive health issues, a position that could put her "at odds" with the Catholic Church"s positions on reproductive rights, according to s familiar with her selection. White House spokesperson Reid Cherlin said, "Like [Obama], she believes that this is an issue where it is important to try and seek common ground and come together to try and reduce the number of unintended pregnancies." Cherlin added, "As a physician, she is deeply committed to the philosophy of putting her patients" needs first when it comes to providing care." The White House would not specifically comment on her views on abortion rights, and an HHS spokesperson says Benjamin is not permitted to speak publicly until she is confirmed. s close to Benjamin, who is Catholic, say that she does support abortion rights, the Post reports. However, several individuals who know Benjamin said her views would not affect her role as surgeon general. David Satcher -- a surgeon general in the Clinton administration who taught community health to Benjamin at the Morehouse School of Medicine -- said, "We all have our religions, but when you speak as the surgeon general to the American people, it"s not about your religion." He added, "I don"t see why the surgeon general has to get involved in a discussion about abortion." Jorge Alsip -- president of the Medical Association of the State of Alabama -- said abortion-related issues occasionally arose when he and Benjamin served on the Alabama State Committee on Public Health. Alsip, who is Catholic, said he does not know her position on the issue, adding, "You kind of have to park your personal beliefs at the door when they conflict with what your role is."Sister Carol Keehan, president and CEO of the Catholic Health Association, said, "This is not pivotal to the surgeon general"s job." She added, "From the perspective of being a practicing Catholic, you can certainly say that it matters. I think being willing to work to reduce (abortion) is a good thing."Robert Lawrence, a director at Johns Hopkins University"s Bloomberg School of Public Health and chair of the board of Physicians for Human Rights, served with Benjamin on the group"s board from 1996 until 2002. He said, "I would think that as surgeon general she would uphold the law of the land, and the law of the land guarantees women a choice for reproductive health." He added, "The charge of the surgeon general is to be the people"s doctor and ensure that all those health services guaranteed under federal law are available to the people" (Thompson, Washington Post, 7/19).

Nightmares Predict Elevated Suicidal Symptoms
Self-reported nightmares among patients seeking emergency psychiatric evaluation uniquely predicted elevated suicidal symptoms, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
Mesoblast Limited's First Patients In Bone Marrow Transplant Trial Show Earlier Engraftment
Australian regenerative medicine company Mesoblast Limited has announced successful results from the first five patients who underwent bone marrow transplantation with haematopoietic stem and progenitor cells expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).
Health Insurance

CEL-SCI To Present Data From Multikine Clinical Trials At National Institutes Of Health (NIH), National Cancer Institute (NCI) Seminar Series

CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced that Dr. Eyal Talor, CEL-SCI"s Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI"s Clinical Center and the Center for Human Immunology, NERD (New Research and Development) Seminar Series, which will take place on Friday July 10, 2009 at the NIH"s Clinical Center located at the main NIH campus, on 9000 Rockville Pike, Bethesda, MD. The title of Dr. Talor"s presentation is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work". In the presentation, Dr. Talor will discuss Multikine"s immunotherapy clinical program for cancer, the unique mechanism of action of Multikine (published in the Journal of Clinical Oncology) and the way Multikine imparts the patient"s own immune response with the ability to mount a robust anti-tumor immune response against his/her tumor. Dr. Talor will also discuss the clinical findings from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians and researchers in the field as a key to improving disease outcome in these patients. Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current Material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH collaborative study will use samples collected from patients with advanced primary Head and Neck cancer (Oral Squamous Cell Carcinoma) during the impending Multikine Pivotal Global Phase III trial and these samples will be tested by the NIH, NCI using Genomic Microarray technology, developed at the NIH, NCI laboratories. About CEL-SCI Corporation CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company"s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation"s SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. CEL-SCI Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009